| Conţinutul numărului revistei |
| Articolul precedent |
| Articolul urmator |
 |
 1978 24 |
| Ultima descărcare din IBN: 2024-03-11 10:03 |
 SM ISO690:2012, , BÎRCA, Ludmila, , , CORNILOV, Stela. Eficienţa preparatului autohton pacovirina în tratamentul mononucleozei infecţioase la copii. In: Curierul Medical, 2014, nr. 1(57), pp. 77-81. ISSN 1875-0666. |
| EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
| Curierul Medical | ||||||
| Numărul 1(57) / 2014 / ISSN 1875-0666 | ||||||
|
||||||
| Pag. 77-81 | ||||||
|
||||||
 Descarcă PDF |
||||||
| Rezumat | ||||||
Background: In the article are presented the clinical results of the treatment of children with infectious mononucleosis where the basic therapy has been combined with the administration of the local drug pacovirin which has antiviral, immunomodulatory, interferonogenic and antioxidant activity. Material and methods: Pacovirin has been administered for one month by 50 mg capsules 2 times a day per os. The object of study has been presented
by 175 patients (84 patients in the experimental group and 91 ones in the comparison group) and the records of the patients surveillance (form 003/e), containing the clinical diagnosis of infectious mononucleosis with Epstein-Barr virus and hepatitis syndrome. The duration of the treatment has been one month, the doses being age-appropriate and applied 2 times a day. Results: The administration of pacovirin as a medicinal remedy in addition to the traditional treatment, in accordance with the method proposed by us, has led to the more intensive normalization of clinical and laboratory indices, decrease of the pathological process and the rapid recovery of the patients, as well as the more intensive normalization of biochemical indices and significant reduction of the duration of the main clinical signs in the experimental group compared with the control group. Conclusions: The drug pacovirin has a positive effect on the main clinical signs of general toxic syndrome and digestive disorders, which have disappeared in a significant number of patients after the treatment. In most patients in the experimental group a decrease in the size of liver and spleen
has been observed through palpatory evaluation by the end of the treatment course with pacovirin. In the the experimental group a positive dynamics of paraclinical indices (Alt, AST and γGTP) has been evident. |
||||||
| Cuvinte-cheie infectious mononucleosis, pacovirin, children, treatment |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-31799</cfResPublId> <cfResPublDate>2014-01-01</cfResPublDate> <cfVol>57</cfVol> <cfIssue>1</cfIssue> <cfStartPage>77</cfStartPage> <cfISSN>1875-0666</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/31799</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Eficienţa preparatului autohton pacovirina în tratamentul mononucleozei infecţioase la copii</cfTitle> <cfKeyw cfLangCode='RO' cfTrans='o'>infectious mononucleosis; children; treatment; pacovirin</cfKeyw> <cfAbstr cfLangCode='EN' cfTrans='o'>Background: In the article are presented the clinical results of the treatment of children with infectious mononucleosis where the basic therapy has been combined with the administration of the local drug pacovirin which has antiviral, immunomodulatory, interferonogenic and antioxidant activity. Material and methods: Pacovirin has been administered for one month by 50 mg capsules 2 times a day per os. The object of study has been presented by 175 patients (84 patients in the experimental group and 91 ones in the comparison group) and the records of the patients surveillance (form 003/e), containing the clinical diagnosis of infectious mononucleosis with Epstein-Barr virus and hepatitis syndrome. The duration of the treatment has been one month, the doses being age-appropriate and applied 2 times a day. Results: The administration of pacovirin as a medicinal remedy in addition to the traditional treatment, in accordance with the method proposed by us, has led to the more intensive normalization of clinical and laboratory indices, decrease of the pathological process and the rapid recovery of the patients, as well as the more intensive normalization of biochemical indices and significant reduction of the duration of the main clinical signs in the experimental group compared with the control group. Conclusions: The drug pacovirin has a positive effect on the main clinical signs of general toxic syndrome and digestive disorders, which have disappeared in a significant number of patients after the treatment. In most patients in the experimental group a decrease in the size of liver and spleen has been observed through palpatory evaluation by the end of the treatment course with pacovirin. In the the experimental group a positive dynamics of paraclinical indices (Alt, AST and γGTP) has been evident.</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-11789</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-276</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13425</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-16116</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-13417</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-11789</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11789-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-276</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-276-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> <cfFamilyNames>Bârcâ</cfFamilyNames> <cfFirstNames>Ludmila</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13425</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13425-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-16116</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-16116-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> <cfFamilyNames>Cornilov</cfFamilyNames> <cfFirstNames>Stela</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-13417</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-13417-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2014-01-01T24:00:00</cfStartDate> </cfPersName_Pers> </cfPers> </CERIF>
|
|
|
